Premarket Clinical Safety Assessment of the ELISIO™-HX
NCT: NCT07058909 · COMPLETED
Brief Summary
The primary safety objective of this study is to evaluate the safety of the use of the high-permeability hemodialyzer series ELISIO™-HX, by showing that the pre-dialysis albumin levels are not affected using the investigational dialyzer. The primary efficacy objective is to evaluate the performance of the use of the high permeability hemodialyzer series ELISIO™-HX, by showing that the clearance rate of middle molecular weight lambda (λ) free light chain (FLC) is improved by using the investigational dialyzer.
Frequently Asked Questions
What is Premarket Clinical Safety Assessment of the ELISIO™-HX?
Premarket Clinical Safety Assessment of the ELISIO™-HX is a clinical trial registered under NCT07058909. Current status: COMPLETED.
What is the status of NCT07058909?
The current status of NCT07058909 (Premarket Clinical Safety Assessment of the ELISIO™-HX) is: COMPLETED.
When did Premarket Clinical Safety Assessment of the ELISIO™-HX start?
Premarket Clinical Safety Assessment of the ELISIO™-HX started on 2025-09-08.
Related Devices
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.